Cargando…

The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development

Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer’s disease and ulcerative colitis. The t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Fan, Xu, Pengfei, Zhai, Yonggong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121873/ https://www.ncbi.nlm.nih.gov/pubmed/30060458 http://dx.doi.org/10.3390/ijms19082189

Ejemplares similares

PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
por: Hong, Fan, et al.
Publicado: (2019)

Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review
por: Grygiel-Górniak, Bogna
Publicado: (2014)

Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors
por: Meqbil, Yazan J., et al.
Publicado: (2022)

Assessment of total, ligand-induced peroxisome proliferator activated receptor γ ligand activity in serum
por: Edwards, Lariah, et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor δ: A Target with a Broad Therapeutic Potential for Drug Discovery
por: Gregoire, Francine M.
Publicado: (2008)

Comparative Evaluation of Gemcabene and Peroxisome Proliferator–Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator–Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease
por: Bisgaier, Charles L., et al.
Publicado: (2018)

Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development
por: Biber, Knut, et al.
Publicado: (2019)

Ligands of the peroxisome proliferator-activated receptor γ inhibit hepatoce llular carcinoma cell proliferation
por: Jin, Zhe, et al.
Publicado: (2017)

CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands
por: Mottin, Melina, et al.
Publicado: (2016)

Ligand-Regulated Heterodimerization of Peroxisome Proliferator-Activated Receptor α with Liver X Receptor α
por: Balanarasimha, Madhumitha, et al.
Publicado: (2014)

An Update on CFTR Drug Discovery: Opportunities and Challenges
por: D’Ursi, Pasqualina, et al.
Publicado: (2022)

AI in drug discovery: Applications, opportunities, and challenges
por: Bittner, Martin-Immanuel, et al.
Publicado: (2022)

Deuterium in drug discovery: progress, opportunities and challenges
por: Di Martino, Rita Maria Concetta, et al.
Publicado: (2023)

Role of Peroxisome Proliferator-Activated Receptor Gamma and Its Ligands in the Treatment of Hematological Malignancies
por: Garcia-Bates, Tatiana M., et al.
Publicado: (2008)

Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-γ Ligands in Lung Cancer
por: Nemenoff, Raphael A., et al.
Publicado: (2008)

The Potential Applications of Peroxisome Proliferator-Activated Receptor δ Ligands in Assisted Reproductive Technology
por: Huang, Jaou-Chen
Publicado: (2008)

Identification of Binding Regions of Bilirubin in the Ligand-Binding Pocket of the Peroxisome Proliferator-Activated Receptor-A (PPARalpha)
por: Gordon, Darren M., et al.
Publicado: (2021)

Ciglitazone, a Peroxisome Proliferator-Activated Receptor Gamma Ligand, Inhibits Proliferation and Differentiation of Th17 Cells
por: Kim, Dong Hyeok, et al.
Publicado: (2015)

Ligand-Activated Peroxisome Proliferator-Activated Receptor β/δ Facilitates Cell Proliferation in Human Cholesteatoma Keratinocytes
por: Zhang, Chen, et al.
Publicado: (2020)

Peroxisome proliferator-activated receptor γ ligand-induced growth inhibition of human hepatocellular carcinoma
por: Rumi, M A K, et al.
Publicado: (2001)

Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-α (PPARα)
por: Tien, Eric S., et al.
Publicado: (2006)

Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease
por: Ward, Jane Elizabeth, et al.
Publicado: (2007)

Monitoring Solution Structures of Peroxisome Proliferator-Activated Receptor β/δ upon Ligand Binding
por: Schwarz, Rico, et al.
Publicado: (2016)

An innovative approach for the treatment of Alzheimer’s disease: the role of peroxisome proliferator-activated receptors and their ligands in development of alternative therapeutic interventions
por: Piemontese, Luca
Publicado: (2019)

Chondrosarcoma and Peroxisome Proliferator-Activated Receptor
por: Nishida, K., et al.
Publicado: (2008)

Metallodrugs are unique: opportunities and challenges of discovery and development
por: Anthony, Elizabeth J., et al.
Publicado: (2020)

Peroxisome Proliferator-Activated Receptor-Targeted Therapies: Challenges upon Infectious Diseases
por: Kim, In Soo, et al.
Publicado: (2023)

The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies
por: Blanco-González, Alexandre, et al.
Publicado: (2023)

Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities
por: Pohl, Laura, et al.
Publicado: (2022)

Peroxisome proliferator-activated receptors, farnesoid X receptor, and dual modulating drugs in hypertension
por: Imig, John D.
Publicado: (2023)

The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Pan-Cancer
por: Huang, Runzhi, et al.
Publicado: (2020)

The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis
por: Xu, Pengfei, et al.
Publicado: (2018)

Structural Insights into Human Peroxisome Proliferator Activated Receptor Delta (PPAR-Delta) Selective Ligand Binding
por: Batista, Fernanda A. H., et al.
Publicado: (2012)

Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer
por: Chandran, Karthic, et al.
Publicado: (2015)

Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
por: Fougerat, Anne, et al.
Publicado: (2020)

Utilizing systems biology to reveal cellular responses to peroxisome proliferator-activated receptor γ ligand exposure
por: Cheng, Vanessa, et al.
Publicado: (2021)

Constitutive Androstane Receptor Agonist, TCPOBOP: Maternal Exposure Impairs the Growth and Development of Female Offspring in Mice
por: Pan, Shijia, et al.
Publicado: (2023)

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges
por: Geerts, Hugo, et al.
Publicado: (2019)

A role for Peroxisome Proliferator-Activated Receptor Beta in T cell development
por: Mothe-Satney, Isabelle, et al.
Publicado: (2016)

Activating Effect of Benzbromarone, a Uricosuric Drug, on Peroxisome Proliferator-Activated Receptors
por: Kunishima, Chiyoko, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_5qlvd40ufdbmqeu0bgmoh96sr6